Actively Recruiting
Study Evaluating UX016 Dosing, Safety, and Effects on Muscle Strength in Adults with GNE Myopathy
Led by Ultragenyx Pharmaceutical Inc · Updated on 2026-10-13
24
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating UX016, an oral drug, for its safety, appropriate dosing, and impact on muscle strength in adults aged 18 to 55 with GNE Myopathy GNEM. This rare muscle disorder is confirmed by genetic testing and is characterized by muscle weakness, particularly in the upper extremities. The study is a randomized, double-blind, placebo-controlled trial led by Ultragenyx Pharmaceutical Inc to assess these outcomes over an extended period. Participants will be randomly assigned in a 31 ratio to receive either UX016 or a placebo. Depending on their sub-cohort, they may receive one or two initial single doses of UX016 at varying amounts before starting daily dosing, or proceed directly to daily dosing at a set dose of either 1g or 2g. After 48 weeks of daily dosing, all participants have the option to enter an extension phase where everyone receives UX016. Placebo recipients also have the chance to receive UX016 during this extension. Throughout the study, participants will undergo various assessments including muscle strength tests like the Upper Extremity Composite score and functional activities scale, as well as plasma and urine tests to monitor UX016 and sialic acid levels. Safety is closely monitored by tracking treatment-emergent adverse events up to week 96, covering both the double-blind and extension periods. The study includes muscle biopsies and requires participants to be able to walk independently at screening. The total study duration extends up to December 2028.
CONDITIONS
Brief Title
First-in-human Study of UX016 in GNEM
Research Team
P
Patient Contact: Trial Recruitment
H
HCP Contact: Medical Information
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here